명인제약

317450KOSPI의약품 제조업

63.5 / 100

Reference Date: 2026-06-10

Financial Score32.0 / 40

News Sentiment17.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and ROE significantly exceeds the industry average is also solid. Plunged 18.3% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Myungin Pharmaceutical specializes in developing and producing CNS-focused specialty pharmaceuticals, including treatments for stroke, Parkinson's disease, and depression, securing the top position in the domestic market according to IQVIA 2025 Q4 data. Leveraging its full-process production capabilities from raw material synthesis to finished products, the company expands partnerships with global pharmaceutical firms and maintains a strong market presence in OTC products as well.

Number of Employees

532people

Average Salary

78.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.52Industry Average 11.936.5Point

Lower than industry avg (good)

PBR

0.81Industry Average 0.894.0Point

In line with industry avg

ROE

12.28Industry Average 4.017.0Point

3.1x industry avg (excellent)

Debt Ratio

0.14Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 6.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

3.5 / 4

Detailed News Sentiment

4 totalPositive 1Neutral 0Negative 3Average Sentiment Score 70

Negative
'주가하락→지분증여' 승계용 꼼수 의혹받는 명인제약, 이행명 회장의.....
명인제약의 주가 하락과 지분 증여 의혹으로 인해 기업 이미지에 부정적 영향이 예상됨.
Negative
주가 하락하자 지분 증여…명인제약, 다시 불붙은 '승계 IPO' 논란
명인제약의 주가 하락으로 인해 회장이 지분 증여를 통해 승계 논란이 재점화되었으며, 투자자들은 손실을 우려하고 있다.
Positive
‘이가탄’ 명인제약 승계 속도…李 회장 자녀에게 지분 증여
명인제약의 승계 계획 발표로 인해 기업의 안정적인 가족 경영 지속과 주가 안정 기대감 증가.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 43,800Won52-week high 121,90052-week low 43,800

1-month return0.0Point

1m -18.28% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-14